Background
Kaposi disease (KD) displays polymorphic manifestations, ranging from minimal cutaneous involvement to extensive visceral disease. Its clinical outline is different in HIV-positive patients compared to the classical non-HIV-related form that is diagnosed more often in elderly patients without other significant immune impairment.
Methods
A retrospective study on KD was performed in two academic centers, tertiary-care hospitals with national addressability in Romania. Two groups were comparatively studied: HIV-infected patients diagnosed in the National Institute for Infectious Diseases "Prof.Dr. Matei Balş" (HIV-positive group), and non-HIV patients diagnosed in the first Clinic of Dermatology, Colentina Clinical Hospital (HIV-negative group). The statistical analysis was performed using IBM SPSS Statistics v.22 (Chicago, USA).
Results
A total number of 71 cases, 30 in the HIV-positive group and 41 in the HIV-negative group were identified. The non-HIV patients were benign European form and immunosuppressed other than HIV, respectively. There was a male predominance, with a male-to-female ratio in HIV-positive and HIV-negative patients of 2:1 and 4.1:1 respectively. The mean age at KD diagnosis was 41.6±15.0 years in HIV-positive and 70.2±11.8 years in HIV-negative patients.
The mean number of comorbidities was 3 in the HIVpositive group compared to 1 in HIV-negative, p = 0.011). In the HIV-positive group, 17 patients (56.7%) were classified Mitsuyasu stage 1, 6 (20%) stage 2, 2 (6.7%) stage 3 and 5 (16.7%) stage 4. In the HIV-negative group, all 41 patients were Mitsuyasu stage 1.
In the HIV-positive group all patients received antiretroviral therapy and only 6 (20%) received other types of targeted therapy for KD: topical (5, 16.7%), systemic (5, 16.7%interferon, etc.), chemotherapy (2, 6.7%), local radiotherapy (2, 6.7%). In the HIV-negative group, all patients received specific treatment, such as: topical (24, 58.5%), systemic (14, 34.1%dapsone, pentoxifylline), chemotherapy (2, 4.9%), local radiotherapy (7, 17.1%), electrocauterization (15, 36.6%), surgical excision (4, 9.8%).
Loss for follow-up appeared to be less frequent in the HIV-positive group (7 patients, 35%) than in the HIVnegative group (35 patients, 85.4%) but occurred faster in the HIV-positive group, after a mean interval of 8.6 ± 3.4 vs. 15.9 ± 37.3 months in HIV-negative group. Overall survival was 60% (HIV-positive) and 100% (HIVnegative).
Conclusion
This work has identified two different outlines of KD, an aggressive progression with high mortality in HIV-positive patients, and a gradual progression, with virtually no short-term mortality, in elderly patients. In the HIVpositive group, very few patients received other types of treatment for KD, apart from antiretroviral therapy.
